Use of transgenic cell lines in mechanistic studies of drug metabolism

被引:6
作者
Gasser, R [1 ]
Funk, C [1 ]
Matzinger, P [1 ]
Klemisch, W [1 ]
Viger-Chougnet, A [1 ]
机构
[1] Hoffmann La Roche Ag, Div Pharmaceut, Preclin Res, CH-4070 Basel, Switzerland
关键词
recombinant enzyme; cytochrome P450;
D O I
10.1016/S0887-2333(99)00035-1
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Heterologously expressed human drug-metabolizing enzyme systems in a variety of hosts (mammalian cell lines, baculovirus/insect cells, yeast and Escherichia toil) have their distinct advantages for particular studies of biotransformation or mechanistic processes, In contrast to classical iii vitro systems such as tissue slices. hepatocytes or subcellular fractions, expressed enzymes allow the study of single enzyme reactions in isolation. Furthermore, metabolic reactions of enzymes expressed only in minor amounts in human tissue can be assessed. Here we present an overview of how recombinant enzymes are bring used in biotransformation studies and we will present several examples of applications of recombinant cytochrome P450 preparations during drug development. It is beyond the scope of this overview to describe all experimental procedures in detail since they art: based on published techniques unless otherwise indicated. Examples of applications of recombinant cytochrome P450 prep preparations include the involvement of human metabolizing enzymes in a metabolic pathway and their metabolic products, mechanistic studies to determine specific drug-drug interactions at the metabolic level and detection of mechanism-based inactivation of drug-metabolizing enzymes. Heterologous expression systems offer a constant and reproducible sourer of human drug-metabolizing enzymes that are easily available by standard laboratory techniques. Considering the constraints on the availability and use of human tissue it is likely that these systems will be widely used in the future, But, because of the unequal distribution of individual drug-metabolizing enzymes in man, extrapolation needs to be done carefully. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:625 / 632
页数:8
相关论文
共 31 条
  • [1] PARTICULAR ABILITY OF CYTOCHROMES P450 3A TO FORM INHIBITORY P450-IRON-METABOLITE COMPLEXES UPON METABOLIC OXIDATION OF AMINODRUGS
    BENSOUSSAN, C
    DELAFORGE, M
    MANSUY, D
    [J]. BIOCHEMICAL PHARMACOLOGY, 1995, 49 (05) : 591 - 602
  • [2] Berglund B., 1992, Indoor Air, V2, P2, DOI [10.1111/j.1600-0668.1992.02-21.x, DOI 10.1111/J.1600-0668.1992.02-21.X]
  • [3] IN-VITRO APPROACHES CAN PREDICT HUMAN DRUG-METABOLISM
    BIRKETT, DJ
    MACKENZIE, PI
    VERONESE, ME
    MINERS, JO
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (08) : 292 - 294
  • [4] INHIBITION BY PAROXETINE OF DESIPRAMINE METABOLISM IN EXTENSIVE BUT NOT IN POOR METABOLIZERS OF SPARTEINE
    BROSEN, K
    HANSEN, JG
    NIELSEN, KK
    SINDRUP, SH
    GRAM, LF
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (04) : 349 - 355
  • [5] Chen LP, 1997, DRUG METAB DISPOS, V25, P399
  • [6] Selective protein covalent binding and target organ toxicity
    Cohen, SD
    Pumford, NR
    Khairallah, EA
    Boekelheide, K
    Pohl, LR
    Amouzadeh, HR
    Hinson, JA
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 143 (01) : 1 - 12
  • [7] Crespi C L, 1997, Adv Pharmacol, V43, P171, DOI 10.1016/S1054-3589(08)60205-7
  • [8] HUMAN CELL-LINES, DERIVED FROM AHH-1 TK+/- HUMAN LYMPHOBLASTS, GENETICALLY-ENGINEERED FOR EXPRESSION OF CYTOCHROMES-P450
    CRESPI, CL
    LANGENBACH, R
    PENMAN, BW
    [J]. TOXICOLOGY, 1993, 82 (1-3) : 89 - 104
  • [9] Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450
    Crespi, CL
    Miller, VP
    Penman, BW
    [J]. ANALYTICAL BIOCHEMISTRY, 1997, 248 (01) : 188 - 190
  • [10] FRANKLIN MR, 1991, METHOD ENZYMOL, V206, P559